

# Nicola J Mccarthy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/952447/publications.pdf>

Version: 2024-02-01

151  
papers

669  
citations

840119

11  
h-index

794141

19  
g-index

275  
all docs

275  
docs citations

275  
times ranked

1436  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interferon- $\beta$ Induces Fas Trafficking and Sensitization to Apoptosis in Vascular Smooth Muscle Cells via a PI3K- and Akt-Dependent Mechanism. <i>American Journal of Pathology</i> , 2006, 168, 2054-2063.	1.9	86
2	Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance. <i>Scientific Reports</i> , 2017, 7, 17693.	1.6	43
3	Increasing the performance of pooled CRISPR-Cas9 drop-out screening. <i>Scientific Reports</i> , 2016, 6, 31782.	1.6	27
4	All together now. <i>Nature Reviews Cancer</i> , 2013, 13, 148-149.	12.8	25
5	Unmasking an oncometabolite. <i>Nature Reviews Cancer</i> , 2012, 12, 229-229.	12.8	20
6	Going places with BANCR. <i>Nature Reviews Cancer</i> , 2012, 12, 451-451.	12.8	19
7	Directed development. <i>Nature Reviews Cancer</i> , 2014, 14, 74-75.	12.8	19
8	Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines. <i>Metabolomics</i> , 2020, 16, 51.	1.4	18
9	Isolation of genes controlling apoptosis through their effects on cell survival. <i>Gene Therapy and Molecular Biology</i> , 2006, 10, 255-262.	1.3	18
10	Epigenetic outcome. <i>Nature Reviews Cancer</i> , 2012, 12, 80-80.	12.8	16
11	Small losses, big gains with microRNAs. <i>Nature Reviews Genetics</i> , 2010, 11, 8-8.	7.7	12
12	Layer by layer. <i>Nature Reviews Genetics</i> , 2011, 12, 804-804.	7.7	11
13	Influencing bad behaviour. <i>Nature Reviews Cancer</i> , 2009, 9, 609-609.	12.8	10
14	MLL makes friends and influences. <i>Nature Reviews Cancer</i> , 2010, 10, 529-529.	12.8	9
15	Regulation and crosstalk. <i>Nature Reviews Molecular Cell Biology</i> , 2010, 11, 390-390.	16.1	8
16	Tracing clones. <i>Nature Reviews Cancer</i> , 2012, 12, 579-579.	12.8	8
17	Rising to the challenge. <i>Nature Reviews Cancer</i> , 2013, 13, 378-378.	12.8	8
18	Oncogene detox programme. <i>Nature Reviews Cancer</i> , 2011, 11, 622-623.	12.8	7

#	ARTICLE	IF	CITATIONS
19	Worth another look?. Nature Reviews Cancer, 2012, 12, 2-2.	12.8	6
20	A TIGAR tale. Nature Reviews Cancer, 2013, 13, 522-523.	12.8	6
21	Seemingly similar. Nature Reviews Cancer, 2014, 14, 214-215.	12.8	6
22	Understanding the prowess of mutant p53. Nature Reviews Cancer, 2014, 14, 385-385.	12.8	6
23	The cancer kaleidoscope. Nature Reviews Cancer, 2014, 14, 151-152.	12.8	6
24	Regulation and crosstalk. Nature Reviews Cancer, 2010, 10, 386-387.	12.8	5
25	Twisting BMI1. Nature Reviews Cancer, 2010, 10, 667-667.	12.8	5
26	Studying the classics. Nature Reviews Cancer, 2011, 11, 386-387.	12.8	5
27	Turnover. Nature Reviews Cancer, 2013, 13, 380-381.	12.8	5
28	Understanding allergy and cancer risk: what are the barriers?. Nature Reviews Cancer, 2015, 15, 131-132.	12.8	5
29	Retroviral insertional mutagenesis implicates E3 ubiquitin ligase RNF168 in the control of cell proliferation and survival. Bioscience Reports, 2017, 37, .	1.1	5
30	ASPP2 gets a polarity complex. Nature Reviews Cancer, 2010, 10, 528-528.	12.8	4
31	REX rules. Nature Reviews Cancer, 2011, 11, 83-83.	12.8	4
32	Target practice. Nature Reviews Cancer, 2011, 11, 315-315.	12.8	4
33	Cut here for differentiation. Nature Reviews Cancer, 2012, 12, 320-321.	12.8	4
34	VEGF suppresses invasion. Nature Reviews Cancer, 2012, 12, 581-581.	12.8	4
35	Darwin's finches. Nature Reviews Cancer, 2012, 12, 317-317.	12.8	4
36	A WEE pointer. Nature Reviews Cancer, 2012, 12, 379-379.	12.8	4

#	ARTICLE	IF	CITATIONS
37	SRC and survival. Nature Reviews Cancer, 2012, 12, 81-81.	12.8	4
38	Leaky effect. Nature Reviews Cancer, 2012, 12, 157-157.	12.8	4
39	Knowing left from right. Nature Reviews Cancer, 2013, 13, 220-221.	12.8	4
40	Losing your SPARC. Nature Reviews Cancer, 2014, 14, 10-11.	12.8	4
41	Master weaver regulates guardian. Nature Reviews Cancer, 2014, 14, 295-295.	12.8	4
42	Flexibility could be important. Nature Reviews Cancer, 2014, 14, 157-157.	12.8	4
43	Hypoxia and XBP1S. Nature Reviews Cancer, 2014, 14, 295-295.	12.8	4
44	An innate response. Nature Reviews Cancer, 2015, 15, 197-197.	12.8	4
45	Route master. Nature Reviews Cancer, 2009, 9, 611-611.	12.8	3
46	Better prospects for BRCA?. Nature Reviews Cancer, 2010, 10, 530-530.	12.8	3
47	Finding your inner activator. Nature Reviews Cancer, 2010, 10, 812-813.	12.8	3
48	Selective justice. Nature Reviews Cancer, 2011, 11, 4-5.	12.8	3
49	Lethal weaknesses. Nature Reviews Cancer, 2011, 11, 538-539.	12.8	3
50	HOTS makes antisense. Nature Reviews Cancer, 2011, 11, 758-759.	12.8	3
51	SIX1 of the best. Nature Reviews Cancer, 2012, 12, 316-316.	12.8	3
52	Megaphone MYC. Nature Reviews Cancer, 2012, 12, 733-733.	12.8	3
53	Targeting menin. Nature Reviews Drug Discovery, 2012, 11, 190-190.	21.5	3
54	Showing a more sensitive side. Nature Reviews Cancer, 2013, 13, 680-680.	12.8	3

#	ARTICLE	IF	CITATIONS
55	The long view. Nature Reviews Cancer, 2013, 13, 76-76.	12.8	3
56	YAP, PTEN and miR-29 size each other up. Nature Reviews Cancer, 2013, 13, 4-5.	12.8	3
57	Lacking in maturity. Nature Reviews Cancer, 2013, 13, 377-377.	12.8	3
58	Targeting an oncometabolite. Nature Reviews Cancer, 2013, 13, 383-383.	12.8	3
59	A multidimensional overview. Nature Reviews Cancer, 2013, 13, 439-439.	12.8	3
60	Making a point. Nature Reviews Cancer, 2014, 14, 6-6.	12.8	3
61	Layer by layer. Nature Reviews Cancer, 2011, 11, 830-830.	12.8	2
62	Self-sufficient. Nature Reviews Cancer, 2011, 11, 6-6.	12.8	2
63	Limiting factors. Nature Reviews Cancer, 2011, 11, 313-313.	12.8	2
64	That's the theory. Nature Reviews Cancer, 2011, 11, 691-691.	12.8	2
65	Adding e for survival. Nature Reviews Cancer, 2012, 12, 230-231.	12.8	2
66	Better by half. Nature Reviews Cancer, 2012, 12, 451-451.	12.8	2
67	Adapt and survive. Nature Reviews Cancer, 2012, 12, 739-739.	12.8	2
68	1+1=2. Nature Reviews Cancer, 2012, 12, 449-449.	12.8	2
69	Enforced compliance. Nature Reviews Cancer, 2012, 12, 153-153.	12.8	2
70	Sensitivity to serine starvation. Nature Reviews Cancer, 2013, 13, 77-77.	12.8	2
71	A surprising competitor. Nature Reviews Cancer, 2014, 14, 73-73.	12.8	2
72	Looking vulnerable. Nature Reviews Cancer, 2014, 14, 217-217.	12.8	2

#	ARTICLE	IF	CITATIONS
73	Running on empty. Nature Reviews Cancer, 2014, 14, 577-577.	12.8	2
74	Micro changes. Nature Reviews Cancer, 2014, 14, 383-383.	12.8	2
75	Mutant BRAF feels the burn. Nature Reviews Cancer, 2015, 15, 455-455.	12.8	2
76	Replicating recurrence. Nature Reviews Cancer, 2009, 9, 613-613.	12.8	1
77	Pushing on through. Nature Reviews Cancer, 2010, 10, 452-453.	12.8	1
78	The ARTS of cell death. Nature Reviews Cancer, 2010, 10, 816-817.	12.8	1
79	RAF complexities spark caution. Nature Reviews Drug Discovery, 2010, 9, 271-271.	21.5	1
80	Tag teams. Nature Reviews Cancer, 2011, 11, 537-537.	12.8	1
81	Silencing heterochromatin. Nature Reviews Cancer, 2011, 11, 760-760.	12.8	1
82	Getting together. Nature Reviews Cancer, 2012, 12, 661-661.	12.8	1
83	Getting together. Nature Reviews Molecular Cell Biology, 2012, 13, 605-605.	16.1	1
84	Catching the X-waves. Nature Reviews Cancer, 2012, 12, 510-510.	12.8	1
85	Genes, genes everywhere.... Nature Reviews Cancer, 2012, 12, 507-507.	12.8	1
86	Staking a claim. Nature Reviews Cancer, 2012, 12, 4-5.	12.8	1
87	WNT branches out. Nature Reviews Cancer, 2013, 13, 81-81.	12.8	1
88	ADORA(2B)tion. Nature Reviews Cancer, 2013, 13, 294-295.	12.8	1
89	The histones have it. Nature Reviews Cancer, 2013, 13, 294-294.	12.8	1
90	Understanding why. Nature Reviews Cancer, 2013, 13, 754-754.	12.8	1

#	ARTICLE	IF	CITATIONS
91	As directed. Nature Reviews Cancer, 2013, 13, 824-825.	12.8	1
92	Mediation by degradation. Nature Reviews Cancer, 2013, 13, 146-146.	12.8	1
93	Horses for courses. Nature Reviews Cancer, 2013, 13, 222-222.	12.8	1
94	Gastric giveaways. Nature Reviews Cancer, 2013, 13, 291-291.	12.8	1
95	Histone mutations take the MYCN. Nature Reviews Cancer, 2013, 13, 382-383.	12.8	1
96	A growing concern. Nature Reviews Cancer, 2014, 14, 154-154.	12.8	1
97	More than just a mutagen. Nature Reviews Cancer, 2014, 14, 213-213.	12.8	1
98	Spotlight on BRG1. Nature Reviews Cancer, 2014, 14, 213-213.	12.8	1
99	Finding the origin. Nature Reviews Cancer, 2014, 14, 387-387.	12.8	1
100	Prognosis based on commitment signature. Nature Reviews Cancer, 2014, 14, 153-153.	12.8	1
101	Put your coat on!. Nature Reviews Cancer, 2015, 15, 319-319.	12.8	1
102	Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines. Metabolomics, 2021, 17, 104.	1.4	1
103	Housing conditions affect tumour growth. Nature Reviews Neuroscience, 2010, 11, 613-613.	4.9	0
104	Double act. Nature Reviews Cancer, 2010, 10, 382-383.	12.8	0
105	“Curiouser and curiouser!” cried Alice. Nature Reviews Cancer, 2010, 10, 532-533.	12.8	0
106	A broad brush. Nature Reviews Cancer, 2010, 10, 600-601.	12.8	0
107	Too much cotton wool?. Nature Reviews Cancer, 2010, 10, 598-598.	12.8	0
108	In need of a boost?. Nature Reviews Cancer, 2010, 10, 742-743.	12.8	0

#	ARTICLE	IF	CITATIONS
109	Ejector seat. Nature Reviews Cancer, 2010, 10, 739-739.	12.8	0
110	Out for the count. Nature Reviews Cancer, 2010, 10, 743-743.	12.8	0
111	Origins. Nature Reviews Cancer, 2011, 11, 80-81.	12.8	0
112	Bad company. Nature Reviews Cancer, 2011, 11, 311-311.	12.8	0
113	Now get out of that.... Nature Reviews Cancer, 2011, 11, 388-389.	12.8	0
114	Shedding light on degradation. Nature Reviews Cancer, 2011, 11, 466-466.	12.8	0
115	A lack of new origins drives fragility. Nature Reviews Cancer, 2011, 11, 626-627.	12.8	0
116	Haem is where the heart is. Nature Reviews Cancer, 2011, 11, 693-693.	12.8	0
117	'NRF said. Nature Reviews Cancer, 2011, 11, 833-833.	12.8	0
118	Now get out of that.... Nature Reviews Drug Discovery, 2011, 10, 414-415.	21.5	0
119	Early exposure is inflammatory. Nature Reviews Immunology, 2011, 11, 157-157.	10.6	0
120	Bad company. Nature Reviews Immunology, 2011, 11, 303-303.	10.6	0
121	Viral vista. Nature Reviews Cancer, 2012, 12, 582-582.	12.8	0
122	Towards a mechanism. Nature Reviews Cancer, 2012, 12, 510-511.	12.8	0
123	Early changes. Nature Reviews Cancer, 2012, 12, 799-799.	12.8	0
124	Unlicensed to kill. Nature Reviews Cancer, 2012, 12, 658-659.	12.8	0
125	The enemy within. Nature Reviews Cancer, 2012, 12, 734-734.	12.8	0
126	Influencing those around you. Nature Reviews Cancer, 2012, 12, 734-734.	12.8	0



#	ARTICLE	IF	CITATIONS
127	Elf represses snail. Nature Reviews Cancer, 2012, 12, 795-795.	12.8	0
128	Radial targets. Nature Reviews Cancer, 2012, 12, 373-373.	12.8	0
129	The great pretenders. Nature Reviews Cancer, 2012, 12, 506-506.	12.8	0
130	No sympathy?. Nature Reviews Cancer, 2012, 12, 584-585.	12.8	0
131	Unlicensed to kill. Nature Reviews Immunology, 2012, 12, 682-683.	10.6	0
132	Multitasking. Nature Reviews Cancer, 2012, 12, 661-661.	12.8	0
133	Divide and conquer?. Nature Reviews Cancer, 2012, 12, 375-375.	12.8	0
134	Targeting menin. Nature Reviews Cancer, 2012, 12, 154-155.	12.8	0
135	Embracing instability. Nature Reviews Cancer, 2013, 13, 521-521.	12.8	0
136	How sweet it is.... Nature Reviews Cancer, 2013, 13, 605-605.	12.8	0
137	Going places with VHL. Nature Reviews Cancer, 2013, 13, 78-78.	12.8	0
138	In the plane. Nature Reviews Cancer, 2013, 13, 606-607.	12.8	0
139	Running in parallel. Nature Reviews Cancer, 2013, 13, 679-679.	12.8	0
140	To have and to hold. Nature Reviews Cancer, 2013, 13, 754-754.	12.8	0
141	WIP1 creates hush and havoc. Nature Reviews Cancer, 2013, 13, 823-823.	12.8	0
142	Nuclear or cytoplasmic?. Nature Reviews Cancer, 2013, 13, 822-823.	12.8	0
143	Keeping TABs on p53. Nature Reviews Cancer, 2013, 13, 682-683.	12.8	0
144	Disrupting a survival signal. Nature Reviews Cancer, 2013, 13, 609-609.	12.8	0

#	ARTICLE	IF	CITATIONS
145	Time for mediation?. Nature Reviews Cancer, 2013, 13, 7-7.	12.8	0
146	In at the beginning. Nature Reviews Cancer, 2013, 13, 147-147.	12.8	0
147	More horses.... Nature Reviews Cancer, 2013, 13, 297-297.	12.8	0
148	A2B via p53. Nature Reviews Cancer, 2013, 13, 441-441.	12.8	0
149	Holding back. Nature Reviews Cancer, 2013, 13, 225-225.	12.8	0
150	MoA on DeMAND. Nature Reviews Genetics, 2015, 16, 498-499.	7.7	0
151	Feed a cold, starve a tumour. Nature Reviews Cancer, 2015, 15, 5-5.	12.8	0